Stock RANI RANI THERAPEUTICS HOLDINGS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Consensus Rani Therapeutics Holdings, Inc.

Equities

RANI

US7530181004

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-04-26 pm EDT 		5-day change 1st Jan Change
6.68 USD +1.83% Intraday chart for Rani Therapeutics Holdings, Inc. +0.15% +101.20%
Mar. 27 Canaccord Genuity Adjusts Rani Therapeutics Price Target to $9 From $21, Maintains Buy Rating MT
Mar. 25 HC Wainwright Adjusts Price Target on Rani Therapeutics to $12 From $16, Keeps Buy Rating MT

Evolution of the average Target Price on Rani Therapeutics Holdings, Inc.

Price target over the last 5 years

History of analyst recommendation changes

6a145b55fb023784deec.U9h6SPcVqunc6K099tP2PMaij96jvF-x6n3d2p7tEug.NuA1fo5Pwb2tjOhTk6quZvbKubnR0Gvg2z-Ki8qcea4_6Qs-u0eb3OSSnQ~4c2d4dc076220de349a0972731a982b2

Analyst Recommendations on Rani Therapeutics Holdings, Inc.

Canaccord Genuity Adjusts Rani Therapeutics Price Target to $9 From $21, Maintains Buy Rating MT
HC Wainwright Adjusts Price Target on Rani Therapeutics to $12 From $16, Keeps Buy Rating MT
Wedbush Cuts Rani Therapeutics Holdings' PT to $8 From $20, Keeps Outperform Rating MT
HC Wainwright Adjusts Price Target on Rani Therapeutics to $16 From $20, Maintains Buy Rating MT
HC Wainwright Adjusts Price Target on Rani Therapeutics to $20 From $22, Keeps Buy Rating MT
Wedbush Lifts Rani Therapeutics Holdings' Price Target to $20 From $19, Keeps Outperform Rating MT
UBS Initiates Coverage on Rani Therapeutics With Buy Rating, $15 Price Target MT
Wedbush Adjusts Rani Therapeutics Holdings Price Target to $19 From $17, Maintains Outperform Rating MT
Wedbush Adjusts Price Target on Rani Therapeutics Holdings to $17 From $28, Keeps Outperform Rating MT
HC Wainwright Initiates Rani Therapeutics Holdings at Buy With $22 Price Target MT
Wedbush Starts Rani Therapeutics Holdings at Outperform With $28 Price Target MT
RANI THERAPEUTICS : Canaccord Genuity Starts Rani Therapeutics Holdings at Buy With $29 Price Target MT
RANI THERAPEUTICS : BTIG Starts Rani Therapeutics Holdings at Buy With $24 Price Target MT
RANI THERAPEUTICS : Cantor Fitzgerald Starts Rani Therapeutics Holdings at Overweight with $23 Price Target MT
RANI THERAPEUTICS : Stifel Starts Rani Therapeutics Holdings at Buy with $24 Price Target MT
RANI THERAPEUTICS : BofA Securities Starts Rani Therapeutics Holdings at Buy with $23 Price Target MT
More recommendations

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
7
Last Close Price
6.56 USD
Average target price
8.857 USD
Spread / Average Target
+35.02%
High Price Target
12 USD
Spread / Highest target
+82.93%
Low Price Target
4 USD
Spread / Lowest Target
-39.02%

Consensus detail

Consensus revision (last 18 months)

Analysts covering Rani Therapeutics Holdings, Inc.

Canaccord Genuity
HC Wainwright
Wedbush
UBS
BTIG
Cantor Fitzgerald
Stifel Nicolaus
BofA Securities

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar
  1. Stock Market
  2. Equities
  3. RANI Stock
  4. Consensus Rani Therapeutics Holdings, Inc.